UK’s Chemical and Pharmaceutical Industry Takes Bold Steps Towards Net Zero with Green Solvents Initiative.

The chemical and pharmaceutical industry, a cornerstone of the UK economy, is embarking on a transformative journey to achieve Net Zero emissions by 2050. With chemical industry revenues reaching £75.2 billion in 2021 and a gross value added of £30.7 billion, the sector plays a critical role in the nation’s prosperity. However, the industry’s reliance on solvents—a major contributor to Greenhouse Gas (GHG) emissions—poses a significant challenge in the transition to a sustainable future.

The Solvent Challenge

Solvents are essential raw materials in small-molecule pharmaceutical manufacturing and are widely used in consumer goods and cosmetics. Despite their utility, solvents have a high aggregate GHG impact and often come with additional negative effects, such as toxicity. While efforts like water-based solvent flow chemistry and solvent recovery and reuse are underway, these solutions alone are insufficient to meet the ambitious Net Zero targets.

To address this, the industry is turning to green chemistry and bio-based or recycled carbon solvents. However, the availability of sustainable solvents remains limited, creating a pressing need for innovation and collaboration.

Sustainable Medicines Manufacturing Innovation Programme

In response, the Sustainable Medicines Manufacturing Innovation Programme has been launched to drive the development and adoption of green solvents. The programme will provide seed funding to support the formation of a consortium and identify barriers to scaling up sustainable solvent integration in medicine manufacturing.

The initiative’s primary goal is to prepare a case for Grand Challenge funding in the Summer of 2025, which will offer large-scale collaborative research and development awards of up to £10 million. These awards will involve at least three partners in the medicines manufacturing supply chain, with only seed funding recipients eligible to apply.

Building the Grand Challenge Consortium

Leading consultancies ERM and Ayming have been tasked with building the Grand Challenge consortium. The firms are calling for participation from a diverse range of stakeholders, including:
✅ Medicine manufacturers producing medicines for the NHS.
✅ Companies outside the medicines industry that use significant volumes of solvents and are investing in reducing Scope 3 emissions from purchased raw materials.
✅ Specialists in green chemistry and chemical producers.

A Unique Partnership for Sustainability

The collaboration between ERM, a global leader in sustainability consulting, and Ayming, known for its expertise in innovation funding, brings together unparalleled capabilities to tackle the complex challenges of decarbonizing pharmaceutical manufacturing.

In a joint statement, the firms highlighted their commitment to accelerating the adoption of low-carbon solutions:
“Bringing together ERM’s expertise in sustainability consulting and Ayming’s proven track record in innovation funding, this partnership is uniquely positioned to tackle the complex challenges of decarbonising pharmaceutical manufacturing. Through funding from Innovate UK, the companies aim to accelerate the adoption of low-carbon solutions, setting new benchmarks for sustainability within the sector.”

A Path Forward

The Sustainable Medicines Manufacturing Innovation Programme represents a critical step towards achieving the UK’s Net Zero goals while ensuring the continued growth and competitiveness of its chemical and pharmaceutical industries. By fostering innovation, collaboration, and investment in green solvents, the initiative aims to create a sustainable future for medicine manufacturing and beyond

Scroll to Top